These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25473002)

  • 1. Optical mammography using diffuse optical spectroscopy for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
    Schaafsma BE; van de Giessen M; Charehbili A; Smit VT; Kroep JR; Lelieveldt BP; Liefers GJ; Chan A; Löwik CW; Dijkstra J; van de Velde CJ; Wasser MN; Vahrmeijer AL
    Clin Cancer Res; 2015 Feb; 21(3):577-84. PubMed ID: 25473002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer.
    Soliman H; Gunasekara A; Rycroft M; Zubovits J; Dent R; Spayne J; Yaffe MJ; Czarnota GJ
    Clin Cancer Res; 2010 May; 16(9):2605-14. PubMed ID: 20406836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
    Kang DK; Kim TH; Han TS; Kim KS; Yim H
    J Comput Assist Tomogr; 2013; 37(3):432-9. PubMed ID: 23674017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
    Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
    Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI.
    Johansen R; Jensen LR; Rydland J; Goa PE; Kvistad KA; Bathen TF; Axelson DE; Lundgren S; Gribbestad IS
    J Magn Reson Imaging; 2009 Jun; 29(6):1300-7. PubMed ID: 19472387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Pickles MD; Lowry M; Manton DJ; Gibbs P; Turnbull LW
    Breast Cancer Res Treat; 2005 May; 91(1):1-10. PubMed ID: 15868426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
    Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
    Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI in the evaluation of breast cancer patient response to neoadjuvant chemotherapy: predictive factors for breast conservative surgery.
    Nadrljanski MM; Miloševic ZC; Plešinac-Karapandžic V; Maksimovic R
    Diagn Interv Radiol; 2013; 19(6):463-70. PubMed ID: 24047722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI and conservative treatment of locally advanced breast cancer.
    Julius T; Kemp SE; Kneeshaw PJ; Chaturvedi A; Drew PJ; Turnbull LW
    Eur J Surg Oncol; 2005 Dec; 31(10):1129-34. PubMed ID: 15905068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis.
    Tran WT; Gangeh MJ; Sannachi L; Chin L; Watkins E; Bruni SG; Rastegar RF; Curpen B; Trudeau M; Gandhi S; Yaffe M; Slodkowska E; Childs C; Sadeghi-Naini A; Czarnota GJ
    Br J Cancer; 2017 May; 116(10):1329-1339. PubMed ID: 28419079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
    Martincich L; Montemurro F; De Rosa G; Marra V; Ponzone R; Cirillo S; Gatti M; Biglia N; Sarotto I; Sismondi P; Regge D; Aglietta M
    Breast Cancer Res Treat; 2004 Jan; 83(1):67-76. PubMed ID: 14997056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Teruel JR; Heldahl MG; Goa PE; Pickles M; Lundgren S; Bathen TF; Gibbs P
    NMR Biomed; 2014 Aug; 27(8):887-96. PubMed ID: 24840393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
    Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
    Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
    Etxano J; Insausti LP; Elizalde A; López Vega JM; Plazaola A; Martínez P
    Acta Radiol; 2015 Nov; 56(11):1300-7. PubMed ID: 25348477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
    Wang XH; Peng WJ; Xin C; Tan HN; Gu YJ; Tang F; Mao J
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):539-43. PubMed ID: 21029700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients.
    Jensen LR; Garzon B; Heldahl MG; Bathen TF; Lundgren S; Gribbestad IS
    J Magn Reson Imaging; 2011 Nov; 34(5):1099-109. PubMed ID: 22002757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new algorithm for automatic vascular mapping of DCE-MRI of the breast: Clinical application of a potential new biomarker.
    Vignati A; Giannini V; Carbonaro LA; Bertotto I; Martincich L; Sardanelli F; Regge D
    Comput Methods Programs Biomed; 2014 Dec; 117(3):482-8. PubMed ID: 25262335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.